Latigo Reports Positive Phase IIb Data for Non-Opioid Acute Pain Candidate

Phase 2positiveLTG-001Positive

AI Analysis

Summary

Latigo announced positive Phase IIb data for LTG-001, its non-opioid acute pain candidate, which met the primary endpoint of SPID48 versus placebo in trial NCT07102459.

Clinical Trial Data

Phase

Phase IIb

Primary Endpoint

Met

NCT ID

NCT07102459

Outcome Details

Achieved primary endpoint of SPID48 (time-weighted sum of pain-intensity difference over 48 hours) with better-than-placebo scores on Numeric Pain Rating Scale

Importance:7/10

Sentiment:

0.75

Phase_2_DataAcute_PainNon_OpioidPrimary_Endpoint_Met

Related Companies

$LTGO

Read the original article

Published by GEN - Genetic Engineering & Biotech News on July 30, 2026 1:00 PM

Read Original